Lean PMOS is real

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. The 2026 Lancet rename consensus also did something else: it consolidated the metabolic evidence that PMOS shows up at every body size, including in people whose body mass index sits within what most clinicians call the "normal" range.

The headline number from that consensus, for the topic of this article: roughly 75 percent of women with PMOS at a lean body weight (defined in the paper as a BMI of 25 or below) have insulin resistance. The figure for people with PMOS overall is approximately 85 percent. The biology that drives PMOS is not weight-dependent. It is what the condition is.

This article is for anyone who has heard "you don’t look like you have PCOS," watched a clinician’s interest fade at a normal BMI reading, or been told their symptoms could not be PMOS because their weight was "fine." Those experiences are well-documented. The science that contradicts them is also well-documented, and now sits as a Tier 1 anchor.

What lean PMOS means

Lean PMOS describes people who meet the diagnostic criteria for PMOS (the same criteria established in the 2023 International Guideline, unchanged by the 2026 rename) and have a BMI of 25 or below. There is no separate diagnostic category. The condition is the same.

A note on terminology. The clinical literature uses several names for this presentation: "lean PCOS," "non-obese PCOS," "normal-weight PCOS," and now increasingly "lean PMOS" in post-rename writing. None of these names changes the underlying picture. The diagnostic criteria are met or not met; the BMI is a number on a chart that influences the visibility of the condition to clinicians, not the condition itself.

Prevalence estimates vary by the population studied. A substantial minority of women with PMOS sit at or below a BMI of 25, often estimated at roughly one in four to one in three, depending on the dataset and the ethnic composition of the sample. In populations of East Asian, South Asian, and East African descent, the proportion is higher, partly because standard BMI cut-offs were developed in predominantly European populations and underestimate metabolic risk at lower body weights in other groups.

The phrase that has done the most damage in this part of the literature is "lean PMOS is a milder form." It is not. The metabolic biology is the same. The diagnostic criteria are the same. The androgen-driven features can be more visible, not less, because the typical body-composition cushioning is absent. The visibility of PMOS to a clinician scanning a chart is what drops at a lower BMI, not the condition.

Why thinness can hide insulin resistance

The mechanism worth understanding is the difference between body composition and body weight.

Subcutaneous fat (the kind stored under the skin, on the hips, thighs, and outer body) is metabolically quieter. Visceral fat (the kind stored around abdominal organs) is metabolically active in ways subcutaneous fat is not. Visceral fat releases inflammatory and metabolic signals that contribute to insulin resistance, regardless of overall body weight. A person can have a "normal" BMI, a body that reads as small or average by visual standards, elevated visceral fat, full insulin resistance, and the full PMOS biochemistry.

This pattern has a name in the metabolic literature: thin outside, fat inside, sometimes abbreviated TOFI. It is well-documented and especially common in women of South Asian and East Asian descent, where insulin resistance and cardiometabolic risk can present at BMI values below the standard cut-offs.

The clinical implication is that BMI alone is a poor screen for metabolic dysfunction in PMOS. The 2023 International Guideline already recommends insulin-aware testing where insulin resistance is suspected, regardless of BMI. The 2026 Lancet consensus reinforces this. In practice, the screening that matters is the same as the screening for PMOS in general: fasting insulin, HOMA-IR, or an oral glucose tolerance test with insulin measurement, alongside the standard PMOS workup of androgens (total and free testosterone, DHEA-S, SHBG), AMH, and ultrasound where indicated. The pillar article on insulin resistance in PMOS covers the test selection in more depth.

The dismissal pattern

If you have been navigating clinical conversations about PMOS at a lean body weight, several phrases probably feel familiar. Each has a documented clinical-pattern problem.

"You’re too thin to have PCOS." Said in the presence of irregular cycles, clear hirsutism, recurrent acne, hair thinning, or fertility difficulty. The implicit assumption is that PMOS equals visible weight gain. The data does not support that assumption. PMOS shows up across the BMI distribution.

"Your labs look normal." Often based on fasting glucose alone, which does not reliably detect early-to-moderate insulin resistance regardless of BMI, and is even less informative when the body composition does not match the metabolic profile. The tests that matter (fasting insulin, HOMA-IR, OGTT with insulin) are not in the standard fasting glucose panel.

"Just track your cycle." Said when androgen-driven features are clearly present. Cycle tracking is useful as observation but does not address the underlying biology. It is sometimes offered as a substitute for a workup.

"It is probably stress."The catch-all dismissal. Stress is real and contributes to metabolic and cycle dysregulation, but "probably stress" is not a diagnostic conclusion when the symptom pattern fits a recognised condition with established criteria.

None of these phrases is malicious. They are pattern-matching shortcuts in a busy clinical environment. They are also a documented contributor to the average diagnostic delay in PMOS, which sits at multiple years for many women and is longer in lean presentations specifically.

What lean PMOS often presents as

The symptom pattern is the same as PMOS at any BMI, with a few features that are particularly common in lean presentations.

Cycle irregularity without weight change. Cycle drift past 35 days, missed periods, or oligomenorrhoea with no significant weight history. The androgenic and insulin contributions to ovulation disruption are not weight-dependent.

Visible androgenic features. Hormonal acne (often jawline and chin pattern, sometimes back and chest), increased terminal hair on the face, abdomen, or thighs, and androgenetic hair thinning at the scalp. These are downstream of elevated free testosterone and reduced SHBG; the insulin contribution is upstream of both, and not weight-gated.

Reactive hypoglycaemia patterns. The post-meal energy crash, the shaky two-to-three-hours-after-eating feeling, and the cravings that follow are common in lean PMOS where the insulin overshoot is present despite a typical body composition. This is the same pattern covered in the mechanism page on the 3pm crash.

Fertility difficulty without an "obvious" cause. Time to conceive can be extended in lean PMOS, particularly where ovulation is irregular but not absent, and standard fertility workups can return mostly unremarkable results if they do not include the PMOS-relevant tests.

The takeaway is not that everyone with these symptoms has PMOS, and not that lean PMOS is hidden in everyone who has them. The takeaway is that a normal BMI does not rule the condition out. The diagnostic criteria do.

What the workup should include

The 2023 International Guideline recommends the same workup regardless of BMI. The components most worth asking about, if any have been left out:

• Androgens: total testosterone, free testosterone, SHBG, and DHEA-S. SHBG is one of the most useful indirect markers of insulin status, and it is sometimes left off the panel.
• Insulin-aware testing: fasting insulin, HOMA-IR, or an oral glucose tolerance test with insulin measurement at two hours. Fasting glucose alone is not sufficient.
• AMH: anti-Müllerian hormone, particularly where ovarian morphology assessment is difficult or declined.
• Ovarian ultrasound: transvaginal where appropriate, by the 2023 Guideline criteria (a follicle count of 20 or more per ovary on transvaginal imaging in adults). Adolescents do not require ultrasound for diagnosis.
• Exclusion testing: TSH (thyroid), prolactin, and 17-hydroxyprogesterone where the clinical picture warrants ruling out other causes.

The care-prep guide on PMOS diagnosis goes deeper on how to bring this workup into a clinical conversation. If a clinician declines to order parts of the panel, the 2023 Guideline is a citable standard.

What helps

The interventions that have evidence in PMOS overall have evidence in lean PMOS, because the underlying biology is the same. Two practical differences are worth naming.

First, weight-loss-framed interventions are not the lever in lean PMOS. They are sometimes offered by default regardless of BMI, and they are not what the evidence supports here. The interventions to pay attention to are the ones that target insulin signalling and androgen patterns directly: sleep, meal composition and sequencing, resistance training, inositol, and (where clinically indicated) metformin and other prescription options.

Second, some of these interventions matter more in lean PMOS than the BMI-elevated form, not less. Resistance training, in particular, is one of the highest-leverage interventions in this context, because muscle mass is the largest single site of insulin-mediated glucose uptake and is often the most movable variable in a body where there is little fat to redistribute.

Specific intervention discussion lives in the insulin resistance pillar; a short version here:

• Sleep. Restricted sleep reduces insulin sensitivity quickly. Foundational, not optional.
• Meal composition and sequencing. Fibre and protein before carbohydrates reduces post-meal insulin spikes meaningfully. Same calories, different signal.
• Resistance training. Two to three sessions a week. Builds insulin-responsive muscle. Particularly leveraged in lean PMOS.
• Inositol. Evidence base for insulin sensitivity, androgen patterns, and ovulation. Generally well-tolerated. Pregnancy and conception contexts warrant a clinician conversation. See the inositol evidence summary.
• Metformin. A clinician-led option with a long history in PMOS care, sometimes used in lean PMOS particularly for fertility support. Decisions belong with a clinician.
• GLP-1 receptor agonists. Newer medications with growing PMOS-specific evidence. Use in lean PMOS is increasing but is more clinician-led than in higher-BMI presentations, and access and cost considerations are significant. See the evidence summary on GLP-1s in PMOS.

What is not on this list: caloric restriction without a metabolic rationale, weight-loss-framed plans applied to a normal-BMI body, or any framing that the body is the problem. Lean PMOS is not a weight situation. Interventions that introduce restriction or moralised eating language are out of scope and can deepen patterns that are harder to recover from than insulin resistance is.

What to ask a clinician

Three questions worth raising in a lean-PMOS conversation.

Can we do an insulin-aware workup, not just fasting glucose? If only fasting glucose has been ordered, ask about fasting insulin, HOMA-IR, or an OGTT with insulin measurement.

What are my SHBG and free testosterone, not just total testosterone? Free testosterone often tells a more accurate story than total testosterone in lean PMOS. SHBG is sometimes the most informative single marker.

Is the workup we are doing the 2023 Guideline workup, regardless of my BMI? The 2023 International Guideline applies the same workup at every BMI. If parts of it have been left out because of a normal-weight reading, the Guideline itself is the citation.

What is still uncertain

Several open questions sit alongside the established picture.

Ethnic-specific BMI cut-offs.The standard "BMI under 25 = lean" threshold under-represents the lean PMOS population in non-European groups, where metabolic risk presents at lower BMI values. Some specialty practices use lower cut-offs (e.g., 23 for South Asian populations); these are not yet harmonised in the international guidelines. The 2028 International Guideline update may revisit this.

PMOS subtypes by insulin status. Some researchers propose distinguishing an insulin-dominant subtype from a reproductive-dominant subtype, with lean PMOS distributing differently between them. The 2026 Lancet consensus acknowledges this work as a recognised direction but does not formalise it. The 2028 Guideline update is the next likely inflection point.

Lean PMOS in adolescents. Adolescent diagnostic criteria are stricter, requiring both hyperandrogenism and oligo-anovulation without ultrasound. Lean adolescent presentations are particularly easy to overlook because pubertal cycle variability overlaps with PMOS-related irregularity. The 2025 adolescent extension to the Guideline is the current reference.

When citing the 2026 Lancet consensus for the 75 percent in lean PMOS figure, the same pharma honoraria disclosure context applies as in the insulin-resistance pillar: several individual authors declared honoraria from companies with adjacent commercial interests. The consensus itself was not pharma-funded. The figure stands on the evidence; the disclosure is context.